

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-062023-000150

Date: 4/7/23

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor* or Fulvestrant - 29
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab +Nab-paclitaxel/Paclitaxel - 2
- Capecitabine as a single agent - 10
- Eribulin as a single agent or in combination - 3
- Everolimus + Exemestane - 2
- Fulvestrant as a single agent - 8
- TK Inhibitors (Neratinib/Lapatinib) - 2
- Parp Inhibitors (Olaparib/Talazoparib)
- Palbociclib + Aromatase Inhibitor* or Fulvestrant - 8 (+46 SA)
- Pembrolizumab - 1
- Platinum (e.g. carboplatin or cisplatin) as a single agent
- Ribociclib + Aromatase Inhibitor* or Fulvestrant
- Sacituzumab Govitecan - 5
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 40
- Taxane and/or Anthracycline in combination - 33
- Trastuzumab as a single agent or in combination - 67
- Trastuzumab conjugates (Trastuzumab emtansine, Trastuzumab deruxtecan) - 17
- Any other active systemic anti-cancer therapy - 9

*aromatase Inhibitors include anastrozole, exemestane and letrozole

2. Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.

IRAS Number	DGH disease area	Project Short title	Project Title	Project site status	No. of participants
134352	Cancer	MAMMO-50	MAMMO-50: Mammographic surveillance in breast cancer patients aged 50 years and over: a randomised controlled tria	Closed to recruitment - in follow up	138
178681	Cancer	PARTNER	Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA	Open	12
95626	Cancer	OPTIMA.	Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis	Open	44
275902	Cancer	Chemobrain_V1.0	Evaluation of cognitive impairment in breast cancer patients treated with cytotoxic chemotherapy	Open	14

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust